Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver

Gene Therapy

Volumn 6, Issue 5, 1999, Pages 749-757

  Kuriyama, S ^a   Tominaga, K ^a   Kikukawa, M ^a   Tsujimoto, T ^a   Nakatani, T ^a   Tsujinoue, H ^a   Okuda, H ^a   Nagao, S ^a   Mitoro, A ^a   Yoshiji, H ^a   Fukui, H ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenovirus; Cyclophosphamide; Gene therapy; Liver; Portal vein; Readministration

Indexed keywords

BETA GALACTOSIDASE; CYCLOPHOSPHAMIDE; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE INDUCTION; GENE THERAPY; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; RAT; REPORTER GENE; T LYMPHOCYTE;

ADENOVIRIDAE; ANIMALS; CYCLOPHOSPHAMIDE; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; IMMUNOSUPPRESSIVE AGENTS; LAC OPERON; LIVER; PORTAL VEIN; RATS; RATS, SPRAGUE-DAWLEY; T-LYMPHOCYTES;

ADENOVIRIDAE; ANIMALIA;

EID: 6544263753     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300894     Document Type: Article

References (42)

1. Strauss SE. Adenovirus infections in humans. In: Ginsberg HS (ed). The Adenoviruses. Plenum Press: New York, 1984, pp 451-496.
2. Rosenfeld MA et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-155.
3. Zabner J et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 75: 207-216.
4. Crystal RG et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-51.
5. Stratford-Perricaudet LD et al. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1990; 1: 241-256.
6. Jaffe H. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nature 1992; 1: 372-378.
7. Kay MA et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994; 91: 2353-2357.
8. Ishibashi S et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-893.
9. Kozarsky KF et al. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe Heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269: 13695-13702.
10. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med 1996; 2: 545-550.
11. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
12. Kaplan JM et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Therapy 1996; 3: 117-127.
13. Fang B et al. Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Therapy 1996; 3: 217-222.
14. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
15. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
16. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-1411.
17. Yei S et al. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Therapy 1994; 1: 192-200.
18. Dong J-Y et al. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther 1996; 7: 319-331.
19. Ilan Y et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology 1998; 27: 1368-1376.
20. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med 1995; 1: 890-893.
21. Weinberg A et al. Enzyme linked immunosorbent assay: determination of anti-adenovirus antibodies in an infant population. Rev Inst Med Trop São Paulo 1989; 31: 336-340.
22. Rosenecker J et al. Adenovirus infection in cystic fibrosis patients: implication for the use of adenoviral vectors for gene transfer. Infection 1996; 24: 5-8.
23. Kuriyama S et al. Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. Anticancer Res 1998; 18: 2345-2352.
24. Vilquin J-T et al. FK506 immunosuppression to control the immune reactions triggered by first generation adenovirus-mediated gene transfer. Hum Gene Ther 1995; 6: 1391-1401.
25. Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996; 7: 1555-1566.
26. Smith TAG et al. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Therapy 1996; 3: 496-502.
27. Ilan Y et al. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. Hepatology 1997; 26: 949-956.
28. Lei D et al. Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats. Hum Gene Ther 1996; 7: 2273-2279.
29. Scaria A et al. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Therapy 1997; 4: 611-617.
30. Yang Y et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 1996; 70: 6370-6377.
31. Kay MA et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 1997; 94: 4686-4691,
32. Jooss K, Turka LA, Wilson JM. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Therapy 1998; 5: 309-319.
33. Weiss A. T lymphocyte activation. In: Paul WE (ed). Fundamental Immunology. Raven Press: New York, 1993, pp 467-504.
34. Kaplan JM, Smith AE. Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum Gene Therapy 1997; 8: 1095-1104.
35. Wang Q et al. Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector. Gene Therapy 1997; 4: 393-400.
36. Nakamura Y et al. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res 1994; 54: 5757-5760.
37. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-200.
38. Miyake S et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 1996; 93: 1320-1324.
39. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ (ed). Methods in Molecular Biology. Humana Press: Clifton, 1991, pp 109-128.
40. Kuriyama S et al. A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector. Cell Struct Funct 1991; 16: 503-510.
41. MacGregor GR et al. Use of E. coli lac Z (β-galactosidase) as a reporter gene. In: Murray EJ (ed). Methods in Molecular Biology. Humana Press: Clifton, 1991, pp 217-235.
42. Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Therapy 1996; 3: 412-420.